Arrowhead Pharmaceuticals’ stock dipped nearly 2% following mixed results from Wave Life Sciences’ trial of WVE-007, which showed only a 0.9% weight reduction over six months—lower than expectations. Leerink analyst Mani Foroohar stated that the market has already priced in significant obesity value for Arrowhead, reflecting its $8.5 billion market cap. In contrast, Wave’s shares plummeted 50% after the data, with analysts expressing concerns over WVE-007’s competitiveness against traditional GLP-1 drugs. Meanwhile, Arrowhead’s candidates aim to reduce body fat while preserving lean muscle, potentially positioning them favorably in the obesity market. Retail sentiment around Arrowhead improved, with shares having quadrupled in value over the past year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://stocktwits.com/news-articles/markets/equity/arwr-stock-slips-on-heels-of-wave-life-sciences-obesity-trial-data-readout/cZ3s2nPRIk9
